LIP lipa pharmaceuticals limited

selling all but gone dry, page-13

  1. 76 Posts.
    re: gone Its still above issue price, for a company that will miss prospectus numbers (on NPAT basis) by 20-25%....there's still potential for more downside on that basis alone.

    Revised FY05 NPAT is now $9.9M. Market Cap is $143.5M (@ $1.60), that puts it on a FY05 PE Multiple of 14.5 times.

    For a no-growth (or at best very smal growth) company, that's probably too high.

    I don't hold.
 
watchlist Created with Sketch. Add LIP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.